Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Leases (2016 - 2025)

Adma Biologics' Current Leases history spans 14 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Leases fell 10.02% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 10.02%, while the annual FY2025 figure was $1.1 million, 10.02% down from the prior year.
  • Current Leases reached $1.1 million in Q4 2025 per ADMA's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.3 million in Q3 2025 to a low of $317910.0 in Q1 2021.
  • Average Current Leases over 5 years is $898699.1, with a median of $981213.5 recorded in 2023.
  • Peak YoY movement for Current Leases: surged 105.72% in 2022, then fell 10.02% in 2025.
  • A 5-year view of Current Leases shows it stood at $591084.0 in 2021, then surged by 53.11% to $905000.0 in 2022, then rose by 15.47% to $1.0 million in 2023, then increased by 16.56% to $1.2 million in 2024, then fell by 10.02% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Current Leases are $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025).